German Real Estate Stock News

XTRA:AFX
XTRA:AFXMedical Equipment

Can ZEISS (XTRA:AFX) Turn New Collaborative Care Software Into a Lasting Digital Moat?

In February 2026, ZEISS Medical Technology launched ZEISS Collaborative Care, a browser-based, cloud-delivered application that lets eye care professionals securely share diagnostic data, manage referrals, and communicate in real time across different clinical settings. By sitting on the ZEISS Healthcare Data Platform and linking with ZEISS FORUM, the software effectively turns existing ophthalmic devices and data silos into a connected collaboration network for more coordinated care. We’ll...
XTRA:AT1
XTRA:AT1Real Estate

Aroundtown (XTRA:AT1) One Off Boost To 55.9% Margin Tests Bullish Profit Narrative

Aroundtown (XTRA:AT1) has wrapped up FY 2025 with fourth quarter revenue of €396 million and basic EPS of €0.14, alongside trailing twelve month revenue of about €1.6 billion and EPS of €0.61. Together, these figures frame a year of sharp earnings recovery from a much weaker prior period. Over recent quarters, the company has seen revenue move from €352.1 million and EPS of €0.25 in Q4 2024 through to €390.7 million and EPS of €0.20 in Q1 2025, with Q3 2025 landing at €389.9 million and EPS...
XTRA:DEZ
XTRA:DEZMachinery

DEUTZ (XTRA:DEZ) Is Down 8.1% After Drone Defence Pivot And BlackRock Stake Rise Has The Bull Case Changed?

Recently, TYTAN Technologies announced a partnership and funding round with DEUTZ, under which DEUTZ will supply and industrialise drive, battery, and energy modules for TYTAN’s drone defence systems, while also preparing to showcase its sustainable drive and energy solutions at CONEXPO Las Vegas. This move marks DEUTZ’s entry into the European unmanned defence systems market and coincides with BlackRock increasing its voting stake above the 3% threshold, highlighting growing institutional...
XTRA:BAYN
XTRA:BAYNPharmaceuticals

Bayer Litigation Deal And Cancer Data Reframe Risk Reward For Investors

Bayer received preliminary court approval for a multibillion euro Roundup class action settlement, addressing a large portion of ongoing litigation. The company reported positive late stage clinical data in prostate cancer, including survival benefits for radium 223 (XOFIGO) in combination therapy and first in human data for a next generation targeted alpha therapy. The FDA cleared expanded capabilities for Bayer's MEDRAD MRXperion MR injection system in the United States. Bayer entered an...
XTRA:BAS
XTRA:BASChemicals

Assessing BASF (XTRA:BAS) Valuation As Shares Show Short Term Momentum But Weaker One Year Return

Why BASF (XTRA:BAS) Is Back on Investors’ Radar BASF (XTRA:BAS) has moved back into focus for some investors after a period of mixed share performance, with a slight gain over the past 3 months and a negative 1 year total return. This combination of recent improvement alongside a weaker 1 year result is prompting closer attention to how the chemical group’s current valuation lines up with its earnings, cash generation, and long established global footprint. See our latest analysis for...
XTRA:DWS
XTRA:DWSCapital Markets

A Look At DWS Group (XTRA:DWS) Valuation After Rising Geopolitical Tensions Involving Iran

Geopolitical shock puts focus on DWS Group GmbH KGaA (XTRA:DWS) A joint U.S. and Israeli strike on Iran has pushed geopolitical risk higher and sharpened market attention on oil prices, safe-haven flows, and volatility in risk assets, including asset managers such as DWS Group GmbH KGaA (XTRA:DWS). See our latest analysis for DWS Group GmbH KGaA. At around €58.35, DWS Group’s recent 1-day share price return of 1.92% comes after a 30-day share price return decline of 6.79%. Its 1-year total...
XTRA:SAP
XTRA:SAPSoftware

A Look At SAP (XTRA:SAP) Valuation After AI-Focused Executive Reorganization

SAP (XTRA:SAP) has reshaped its leadership around artificial intelligence, creating a new Customer Value Group under Chief Customer Officer Thomas Saueressig to align sales, services and support and push adoption of its cloud and AI products. See our latest analysis for SAP. Despite the leadership reshuffle and a busy run of announcements, including the Teradata legal settlement, updated bonus framework and a proposed dividend of €2.50 per share, SAP’s recent share price performance has been...
XTRA:EOAN
XTRA:EOANIntegrated Utilities

A Look At E.ON (XTRA:EOAN) Valuation After 2025 Earnings And Higher Dividend Proposal

E.ON (XTRA:EOAN) has drawn fresh attention after reporting full year 2025 earnings and proposing a higher dividend of €0.57 per share, a 4% increase, despite lower sales and net income. See our latest analysis for E.ON. The proposed dividend increase and the recent earnings release come after a strong run in E.ON’s shares, with a 90 day share price return of 21.11% and a 1 year total shareholder return of 60.64%. This suggests momentum has been building even as reported net income moved lower...
XTRA:RWE
XTRA:RWERenewable Energy

RWE Fusion Alliance Adds Long Term Optionality To Valuation Debate

RWE (XTRA:RWE) has entered into an agreement with Proxima Fusion, the Max Planck Institute and the State of Bavaria to commercialize fusion energy in Europe. The partners plan to work toward building what they aim to be the world's first commercial stellarator fusion power plant. The alliance focuses on moving fusion technology from research settings into industrial scale deployment in Europe. RWE shares most recently traded at €53.34, with the stock up 13.7% year to date and 81.0% over the...
XTRA:ALV
XTRA:ALVInsurance

Allianz (XTRA:ALV) Valuation Check After Earnings Beat, Higher Dividend, 2026 Guidance And €2.5b Buyback

Allianz (XTRA:ALV) is in focus after reporting fourth quarter and full year 2025 earnings, proposing a higher dividend for 2025, issuing 2026 operating profit guidance, and confirming a new share buyback plan. See our latest analysis for Allianz. The latest earnings, higher proposed dividend and fresh €2.5b buyback come after a mixed period for the share price, with a 1 day share price return of 1.01% but a weaker 7 day move of 5.90% and a 30 day share price return of 5.33%. At the same time,...
XTRA:S92
XTRA:S92Electrical

A Look At SMA Solar Technology (XTRA:S92) Valuation After 2025 Results And Mixed Segment Performance

SMA Solar Technology (XTRA:S92) is back in focus after reporting 2025 results that showed a 0.9% sales decline, sharply lower EBITDA tied to impairments and restructuring, and contrasting performances across its core segments. See our latest analysis for SMA Solar Technology. The earnings update landed alongside a sharp 9.7% 1 day share price return to €32.0. However, the 30 day share price return of 11.0% and the year to date share price return of 10.5% point to fading momentum after a...
XTRA:KBX
XTRA:KBXMachinery

Knorr Bremse (XTRA:KBX) Valuation Check As 2026 Earnings Guidance Sets New Expectations

Guidance highlights and why they matter for investors Knorr-Bremse (XTRA:KBX) has issued earnings guidance for 2026, stating that it expects revenues between €8,000 million and €8,300 million and an operating EBIT margin of around 14%, assuming stable macro and geopolitical conditions. For investors, this guidance provides a concrete reference point for comparing the current share price with management’s expectations for the business, particularly in light of Knorr-Bremse’s role in rail and...
XTRA:MTX
XTRA:MTXAerospace & Defense

MTU Aero Engines (XTRA:MTX) Q3 10.6% Net Margin Tests Bearish Profitability Narratives

MTU Aero Engines (XTRA:MTX) has put up another solid set of numbers, with Q3 2025 revenue at €2.1b and EPS of €4.63, sitting within a trailing twelve month picture of €8.5b in revenue and EPS of €16.61. Over the past few quarters, the company has seen revenue move between €1.7b and €2.1b per quarter, while quarterly EPS ranged from €2.40 to €5.39. This has fed into trailing net income of €897m and a 10.6% net margin. For investors, that margin profile is a key signal, as it frames how much of...
XTRA:RDC
XTRA:RDCConsumer Retailing

Redcare Pharmacy Q3 Loss Revives Debate On Profitability Timeline And Bullish Growth Narratives

Redcare Pharmacy (XTRA:RDC) has put another quarter on the board with Q3 FY 2025 revenue of €719.2 million and a net loss of €7.2 million, as the business continues to balance top line scale with the cost of growth. Over the past few reported periods, revenue has moved from €560.7 million in Q2 2024 to €675.1 million in Q4 2024, then into the €709.2 million to €719.2 million range in the first three quarters of FY 2025, while EPS swung from a loss of €1.30 in Q4 2024 to a profit of €0.46 in...
XTRA:NEM
XTRA:NEMSoftware

Nemetschek (XTRA:NEM) Valuation Check As New India Leadership Targets Construction Digitalisation

Nemetschek (XTRA:NEM) has appointed Alok Sharma as managing director and vice president for India, drawing attention to how its stock reflects ambitions in a construction market where digital tools are gaining traction. See our latest analysis for Nemetschek. The latest appointment in India comes as momentum around Nemetschek’s share price has been mixed, with a 1-day share price return of 1.48% and 7-day share price return of 6.93%, contrasting with a 90-day share price return decline of...
XTRA:MBG
XTRA:MBGAuto

Mercedes-Benz Group (XTRA:MBG) Valuation Check As Buybacks Continue And Bank Of America Takes 3% Stake

Why Mercedes-Benz Group Stock Is Back in Focus Mercedes-Benz Group (XTRA:MBG) is back on investors’ radar after the company continued its share buyback in late February and Bank of America reported crossing the 3% voting rights threshold. Together, these moves highlight ongoing capital management decisions and shifts in the shareholder base, providing additional context if you are tracking the stock’s return profile and ownership structure. See our latest analysis for Mercedes-Benz...
XTRA:GBF
XTRA:GBFCommercial Services

Bilfinger (XTRA:GBF) Margin Decline Tests Bullish Energy Transition Narratives

Bilfinger (XTRA:GBF) has put solid top line and bottom line figures on the table, with Q3 2025 revenue of €1.4b and basic EPS of €1.48, alongside net income of €55m that keeps the year’s earnings run rate firmly in focus. The company has seen quarterly revenue move from €1.30b in Q2 2024 to €1.36b in Q4 2024 and then to €1.38b in Q3 2025. Basic EPS has ranged from €1.25 in Q2 2024 to €1.39 in Q4 2024 and €1.48 in Q3 2025, giving investors a clear view of recent trading momentum. With the...
XTRA:8TRA
XTRA:8TRAMachinery

Traton (XTRA:8TRA) Margin Compression To 4% Reinforces Bearish Profitability Narrative

Traton FY 2025 Q3 headline numbers set the tone Traton (XTRA:8TRA) has put fresh numbers on the table for FY 2025 Q3, reporting revenue of €10.4b and basic EPS of €0.65, with net income excluding extra items at €324m as investors weigh how the business is tracking through the year. The group has seen quarterly revenue move from €11.6b and EPS of €1.17 in FY 2024 Q2 to €12.2b and €1.49 in FY 2024 Q4, then to €10.6b and €0.93 in FY 2025 Q1 and €11.3b and €0.49 in FY 2025 Q2. This provides a...
XTRA:SY1
XTRA:SY1Chemicals

Symrise (XTRA:SY1) Margin Expansion To 10.2% Tests Bearish Profitability Narrative

How Symrise’s FY 2025 Results Landed Against Expectations Symrise (XTRA:SY1) has just put fresh numbers on the table, with first half FY 2025 revenue at €2.6b and basic EPS of €1.92. Trailing 12 month EPS sits at €3.63 on revenue of €5.0b and net income of €506.9m. The company has seen revenue move from €4.9b to about €5.0b over the past year on a trailing 12 month basis, with basic EPS stepping up from €2.81 to €3.63 and net income from €392.4m to €506.9m. Together, these figures provide a...
XTRA:LHA
XTRA:LHAAirlines

Lufthansa (XTRA:LHA) Valuation Check As Middle East Tensions And Labor Strains Disrupt Operations

Why Lufthansa is suddenly back in focus Deutsche Lufthansa (XTRA:LHA) is back on many watchlists after Middle East tensions disrupted key air corridors, pushed fuel costs higher, and coincided with labor disputes and an earnings update scheduled for March 6, 2026. See our latest analysis for Deutsche Lufthansa. At a latest share price of €8.402, Deutsche Lufthansa has seen short term pressure, with a 7 day share price return of an 8.51% decline and a 30 day share price return of a 5.85%...
XTRA:BMW
XTRA:BMWAuto

Assessing BMW (XTRA:BMW) Valuation After Recent Share Performance And Undervaluation Signals

Recent performance snapshot for Bayerische Motoren Werke Bayerische Motoren Werke (XTRA:BMW) has drawn investor attention after recent share price moves, with the stock last closing at €82.86 and showing mixed returns over the past week, month and past 3 months. Over 1 year, the total return sits at 4.88%, while longer horizons show a 0.22% total return over 3 years and 36.31% over 5 years. This provides investors with several time frames to compare recent trading with past performance. See...
XTRA:WUW
XTRA:WUWInsurance

Assessing Wüstenrot & Württembergische (XTRA:WUW) Valuation After Dividend Hikes And Fresh Foreign Capital Interest

Wüstenrot & Württembergische (XTRA:WUW) has drawn investor attention after a series of dividend increases and renewed foreign capital interest, reinforcing its image as a conservative, diversified play across insurance, housing finance, and banking. See our latest analysis for Wüstenrot & Württembergische. At a latest share price of €16.16, Wüstenrot & Württembergische has paired a 90 day share price return of 14.12% with a 1 year total shareholder return of 31.64%. This suggests momentum has...
XTRA:BEI
XTRA:BEIPersonal Products

Beiersdorf (XTRA:BEI) Margin Resilience Softens Bearish Cost Concerns In Latest FY 2025 Results

Beiersdorf (XTRA:BEI) has posted its latest FY 2025 numbers with first half revenue of €5.2b and basic EPS of €2.47, while trailing 12 month figures show revenue of €9.9b and EPS of €4.25. The company has seen revenue move from €4.7b and EPS of €1.48 in 2H 2024 to €5.2b and EPS of €2.47 in 1H 2025. Trailing net income on a 12 month basis stands at €939m, alongside a profit margin that sits slightly higher than the prior year. That mix of steady earnings growth and a modestly firmer margin...
XTRA:ADS
XTRA:ADSLuxury

Is There Now An Opportunity In Adidas (XTRA:ADS) After Recent Share Price Slide

If you are wondering whether adidas shares are starting to look interesting or still too expensive, you are not alone. Many investors are asking what the current price really reflects about the business. The stock closed at €141.80, with a 10.5% decline over 7 days, a 5.6% decline over 30 days, a 15.3% decline year to date, a 39.9% decline over 1 year and a 48.9% decline over 5 years. This naturally raises questions about how expectations and risk are being priced in. Recent coverage around...